Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care - Psyence Biomedical ( NASDAQ:PBM )
Psyence Biomedical Ltd. PBM announced a major milestone on Monday with the initiation of the first clinical trial site in Australia for its Phase IIb study on nature-derived psilocybin as a potential treatment for Adjustment Disorder in patients receiving palliative care.
| Ticker |
Sentiment |
Impact |
|
PBM
|
Somewhat Bullish
|
39 %
|
|
PSYGF
|
Somewhat Bullish
|
30 %
|
